Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 739
- Registration Number
- NCT01555151
- Locations
- 🇺🇦
Novartis Investigative Site, Vinnytsia, Ukraine
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT01552629
- Locations
- 🇩🇪
Novartis Investigative Site, Kiel, Germany
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 436
- Registration Number
- NCT01551173
- Locations
- 🇨🇳
Novartis Investigative Site, Changsha, Hunan, China
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
Phase 4
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 339
- Registration Number
- NCT01551212
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT01545817
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT01546532
- Locations
- 🇵🇱
Novartis Investigative Site, Warszawa, Poland
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: INC280
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT01546428
- Locations
- 🇯🇵
Novartis Investigative Site, Fukuoka, Japan
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
Phase 4
Completed
- Conditions
- Iron Overload
- Interventions
- Drug: Desferasirox
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT01546415
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT01545726
- Locations
- 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Phase 3
Completed
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1147
- Registration Number
- NCT01544595
- Locations
- 🇬🇧
Novartis Investigative Site, Nuneaton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath